Australia

With a staff of more than 450 and a budget of over $50 million, Burnet has the capacity, expertise and strategic vision to tackle the key health issues affecting not only Australians in marginalised communities, but poor and vulnerable communities globally.

Major health issues such as sexually-transmitted diseases, blood-borne diseases (hepatitis C), HIV, alcohol and drug misuse and related behaviours are not limited by geography. Improving the health of Australians in highly vulnerable communities, such as prisoner populations, sex workers and injecting drug users are also a key focus of our work.

At our headquarters in Melbourne, our dedicated teams of laboratory scientists and population health researchers work closely together across technical and population health thematic areas to explore new ways to address complex health problems..

High quality, policy relevant and innovative research is undertaken Australia-wide and the outcomes are published and reported widely.

Our unique approach of linking medical research with public health action sets us apart from other Australian institutions.

Offices

Melbourne

85 Commercial Road
Melbourne, Victoria
Australia

Contact Details

For more information about our work in Australia, please contact:

Tracy Parish

Executive General Manager, Marketing and Communications

Telephone

+61385062321

Email

[email protected]



Current Projects

  • A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression

  • A unique approach to anti-inflammatory immune therapy

  • Access Point Of Care Initiative

  • ACCESS: The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmitted Infections

  • ACE2 inhibitors for treatment of COVID-19

  • Age-related immune dysfunction may underpin poor COVID-19 outcomes in the elderly

  • Ageing Well with HIV

  • ANCP: Improving maternal and child health outcomes in Myanmar

  • Antibody engineering to study responses mediating protective immunity

  • Antibody mAbs to destroy infection: engineering the next generation treatments

  • APPRISE - Centre for Research Excellence

  • Attitudes to drug use among East African migrants in Melbourne’s western suburbs

  • Australia Awards Fellowship: KICK-AMR to Address Antimicrobial Resistance

  • Barriers to hepatocellular carcinoma screening uptake in Victoria

  • Breaking the cycle: supporting people with drug use histories to avoid reincarceration

  • Broadly neutralising anti-HIV antibodies and Fc Receptor function

  • Building a Centre of Excellence for Research and Training for DR-TB in Daru, Papua New Guinea

  • Characterisation of retroviruses in bats

  • Clinical studies on malaria

  • co-EC Study: Eliminating hepatitis C/HIV coinfection

  • Community-Based Rapid HIV Testing Services

  • Coping with COVID-19: Young people’s health and wellbeing in Australia

  • COVASIM: Modelling COVID-19

  • COVID-19 antigens for PoC test development

  • COVID-19 Journey Project

  • COVID-19 Vaccine Development

  • CREIDU: Centre for Research Excellence into Injecting Drug Use

  • DARE C: ATAHC II Substudy

  • Decision science using Optima

  • Demonstrating the impact of next generation Cepheid tools in TB

  • Developing new antimalarial drugs that block protein trafficking

  • Developing vaccines against malaria

  • Development of a novel prophylactic vaccine candidate for HIV-1

  • Development of a point-of-care test for neonatal sepsis

  • Discovering the mechanisms and targets of immunity against malaria

  • Discovery of new treatments for myeloma and myelogenous leukemia

  • EC Partnership: Eliminate Hepatitis C Partnership

  • EDRS: Ecstasy and related Drugs Reporting System

  • Eliminate Hepatitis C Australia Partnership: EC Australia

  • Engaging men to improve family health and prevent gender-based violence

  • ESCAPE-TB: Enhanced screening and preventive therapy for TB in Daru, PNG

  • Evaluating a highly sensitive rapid malaria diagnostic in PNG

  • Evaluating the WHO Labour Care Guide in clinical settings

  • Evaluation of the Multicultural Drug and Alcohol Service

  • EVE-M

  • Evidence and action for malaria elimination in Myanmar

  • Examining interventions targeting high-risk drinking among young Australians

  • Exploring alcohol and other drug use among migrant communities in Victoria

  • Feasibility study for a potential medically supervised injecting centre/drug consumption service for the ACT

  • Gender Counts

  • Getting to the heart of cardiovascular disease in HIV

  • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

  • HCV Elimination Modelling

  • Healthy Mothers, Healthy Babies

  • Hepatitis B discrimination and health service access.

  • Hepatitis C and injecting networks

  • Hepatitis C brief reports

  • HepSeeVax: Proof-of-concept study of an HCV vaccine candidate

  • HIV Prevention Cohort

  • HMHB - Health Services for Postnatal and Infancy Care

  • HMHB: Quality of Pregnancy, Childbirth and Newborn Health Services Study

  • HMHB: The impact of nutrition, malaria and STIs on pregnant women and infants

  • Host red blood cell modification sustains the virulence of malaria parasites

  • Identifying the barriers to hepatitis B clinical management: the perspectives of people with hepatitis B.

  • Identifying the structural enablers to the clinical management of people with hepatitis B in general practice: a qualitative investigation

  • IDRS: Illicit Drug Reporting System

  • IgA and staphyloccocal aureus immune evasion

  • Immunity to malaria and infectious diseases during pregnancy

  • Improving Hepatitis B Virus screening in general practice in Victoria

  • Integrated Multi-Sectoral Approach (IMSA) To Improve The Sexual And Reproductive Health Of Adolescents In Magway, Myanmar

  • Iron deficiency anaemia and adverse birth outcomes in a malaria-endemic region of Papua New Guinea

  • Major advances in understanding malaria immunity and biology

  • Mapping of COVID-19-related pregnancy and perinatal research in Australia

  • Mechanism of antimalarial drug action

  • Methods for improved sensitivity of lateral flow tests

  • National COVID-19 Clinical Evidence Taskforce

  • Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals

  • Needle and Syringe Program (NSP) Snapshot Study

  • Neutralising antibody assays for COVID-19

  • New approaches to the treatment of lupus

  • New media and technology in health promotion practice

  • Novel reagents for the serological diagnosis of tuberculosis

  • Optimising Quarantine Study

  • Pornography and Young People

  • PrEPX: Rapid scale-up of HIV pre-exposure prophylaxis (PrEP)

  • Project Geldom

  • PRONTO! Rapid HIV point-of-care testing in Victoria

  • Rapid and accurate diagnosis of TB: New trial in PNG

  • Rapid review of maternal health recommendations related to the COVID-19 pandemic

  • RID-TB: Reducing the Impact of Drug-Resistant TB in Western Province, PNG

  • Sex, Drugs, and Rock'n'Roll (Big Day Out Study)

  • Sexual and reproductive health in Asia and the Pacific

  • SHARP: Screening for Hepatitis in At-Risk Populations

  • SHARP: Sexual Health And Risk Prevention Study

  • Social Networks and the Hepatitis C Virus

  • SRH survey of Chinese-speaking international students

  • SRHIP: Sexual & Reproductive Health Integration Project

  • Stakeholder experiences of father engagement interventions in low- and middle-income countries

  • STRIVE PNG: strengthening surveillance and response for vector-borne pathogens in PNG.

  • SuperMIX: The Melbourne Injecting Drug User Cohort Study

  • TAIPAN: HIV cascade surveillance

  • Targeting HIV-infected macrophages to achieve an HIV cure

  • The Australian Trial in Acute Hepatitis C (ATAHC)

  • The B-VAX Project: Hep B vaccinations for people who inject drugs

  • The impact of viral infections on immune ageing

  • The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

  • The Mbereko + Men Model: Rural Zimbabwe

  • The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

  • The Optimise Study: Recruitment Information

  • The oral health of people who inject drugs (PWID)

  • The persistence of HIV in monocytes and macrophages

  • The PharmEC REACH study

  • The production of guidance for the laboratory sector to prepare for emergency situations

  • The QuickStart Study

  • The role of monocytes in the development of cardiovascular disease

  • The Social and Cultural Determinants of TB in Daru [SCuD-TB Daru – Study 1]

  • traQ Study: Transparent Risk Assessment of Quarantine

  • TRYP: Transitions and Risk in Young People project

  • Understanding how HCV evades the immune system

  • Understanding the connection between inflammation and cancer

  • Vaccines against Plasmodium vivax and P. falciparum malaria

  • What drives hepatitis C reinfection?

Past Projects

  • ALT point-of-care diagnostic to detect liver disease

  • Characterisation of bat intracellular restriction factors

  • Collaborative Community Checklists for Immunisation (CCCI)

  • EC Australia: The vital missing link to eliminating hepatitis C

  • Hepatitis B infection in Australian prisons

  • PATH Cohort Study

  • Smartphone apps for alcohol health promotion

  • Strategies to reduce malnutrition with allocative efficiency analyses

  • TB-MAC Multi-modelling Exercise

  • The Drug Policy Modelling Program (DPMP)

  • Victorian Pharmaceutical Opioid Monitoring Project